Gene · 3003
NIH grants2,103
NIH grants whose papers are about the gene, through NIH's grant-paper links.
321 to 340 of 2,103
Download this page as JSON| Grant | Title | GZMK papers | Newest fiscal year |
|---|---|---|---|
| R01AR078688 | Multi-racial genetic analysis of hidradenitis suppurativa | 1 | 2025 |
| R01AR078769 | Regulation of T helper cell functions by aryl hydrocarbon receptor | 1 | 2025 |
| R01AR080068 | Dermal Lymphatic Transport and Cutaneous Immune Balance | 1 | 2025 |
| R01AR080436 | Interrogating unique DC adaptations to tissue to promote barrier immunity and tolerance | 1 | 2025 |
| R01AR080659 | Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases | 1 | 2025 |
| R01AR082203 | Investigating monocyte activation pathways in lupus | 1 | 2025 |
| R01CA142746 | Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines | 1 | 2025 |
| R01CA148761 | Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | 1 | 2025 |
| R01CA173481 | Preclinical analyses of advanced prostate cancer in genetically-engineered mice | 1 | 2025 |
| R01CA173852 | Role of p21 activated kinase in Leukemogenesis | 1 | 2025 |
| R01CA178393 | Genomic Architecture of LGL Leukemia | 1 | 2025 |
| R01CA183929 | Molecular mechanisms of prostate cancer metastasis | 1 | 2025 |
| R01CA201380 | Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation | 1 | 2025 |
| R01CA206517 | Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes | 1 | 2025 |
| R01CA217987 | Metabolic barriers to T cell activation in clear cell renal cell carcinoma | 1 | 2025 |
| R01CA220327 | Racial Difference in Prostate Cancer | 1 | 2025 |
| R01CA225028 | Tissue Resident memory T cell responses to cancer | 1 | 2025 |
| R01CA226909 | Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC | 1 | 2025 |
| R01CA229529 | Studying macrophage polarization in search for predictive and prognostic markers of breast cancer | 1 | 2025 |
| R01CA238039 | Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3003/grants?page=17